FDA vote clears path but lower prices pressure future margins
- Galleri test volume grew 24% year over year in the third quarter of 2026.
- Screening revenue accounted for over 99 percent of total revenue in the latest quarter.
- A recent price promotion dropped the average selling price to roughly $660 per test.
- A favorable FDA advisory committee vote cleared the path for a potential premarket approval in early 2027.
- The suspended legacy Illumina royalty returns in late December 2026 and will compress gross margins.
- New Epic integrations have rolled out to make prescribing easier within major health systems.
Balancing demand and price
GRAIL is trying to make Galleri a standard cancer screen. The pitch is simple. It offers one blood test that looks for a shared cancer signal across more than 50 cancer types, then points to where that signal may have started. The hard part is proving that this test should be used and paid for broadly.
The bull case centers on steady demand and a derisked path to FDA approval. Galleri sales volume grew 24% year over year in the third quarter of 2026. A favorable FDA advisory committee vote in September cleared a major hurdle, setting up a potential premarket approval in early 2027. The company also rolled out its first live Epic integration, removing friction for doctors in major health systems.
The bear case highlights weakening unit economics, rising competition, and returning royalties. Management dropped the average selling price to roughly $660 via a price promotion to drive volume ahead of approval. At the same time, the legacy Illumina royalty will resume in late December 2026. This will severely compress gross margins just as prices hit new lows. Adding to this burden, newly filed securities class actions could divert management attention and incur substantial legal costs.
The next year is about proof and cash. Investors need to see average selling prices stabilize and margins survive the returning Illumina royalty. The Medicare MCED law helps the long-term case, but coverage begins in 2029 and still depends on final FDA approval and evidence that payors accept.
One test pays the bills
GRAIL makes most of its money by selling the Galleri test in the United States. Galleri is sold today as a Laboratory Developed Test, which means it is offered through a lab pathway rather than as a fully FDA-approved medical device. Customers come through primary care doctors, health systems via direct Epic electronic health record integrations, self-insured employers, and life insurance providers.
In the third quarter of 2026, screening revenue was over 99 percent of total revenue, coming in at $37.3 million. That makes the business simple to understand, but also highly concentrated. If Galleri adoption slows, pricing weakens, or regulators and payors push back, there is no large second business to soften the hit.
A smaller development services business serves biopharma and clinical customers using the company methylation platform. That line was less than 1 percent of third quarter revenue, generating $0.2 million. GRAIL has cut back spending on other product programs so it can focus on Galleri commercialization and the FDA premarket approval submission.
The long-term money path is reimbursement. Today, GRAIL is building demand before broad Medicare coverage. The Medicare MCED law creates a national coverage process for FDA-approved early detection tests, but the benefit starts in 2029. That timing matters because GRAIL may need more capital if cash burn stays high before coverage arrives.
Galleri, plus smaller options
Galleri
Galleri is the core product and the main revenue driver. It is a blood-based multi-cancer early detection test designed to detect a shared cancer signal across more than 50 cancer types and predict where the signal came from.
Galleri FDA PMA program
The PMA path is not a separate test, but it is central to the value of Galleri. FDA approval is needed for the broad reimbursement plan tied to the Medicare MCED law.
Research-use-only services
GRAIL offers research-use-only services to biopharma partners through its methylation platform. This is much smaller than screening revenue and is part of development services.
Development services
Development services revenue comes from biopharmaceutical and clinical customers. It made up less than 1 percent of third quarter 2026 revenue.
Diagnostic aid for cancer program
The diagnostic aid for cancer program is not the focus today. GRAIL has substantially decreased investment in this program to direct resources toward Galleri.
Minimal residual disease program
The minimal residual disease program has also been de-prioritized. It may retain future optional value, but the current company story is Galleri.
Revenue mix is concentrated
The segment mix is from the third quarter of 2026. Screening revenue was over 99 percent of total revenue, making changes in Galleri volume or price the main driver for the whole company.
What could break the thesis
ASP drops meet returning royalties
High impact · High oddsAverage selling prices fell to roughly $660 due to a price promotion intended to drive volume. Simultaneously, the legacy Illumina royalty resumes in late December 2026. If the company cannot reduce testing costs fast enough, this combination will severely compress gross margins.
FDA final label restrictions
High impact · Medium oddsWhile the FDA advisory committee voted favorably, final premarket approval is expected in early 2027. The FDA could impose strict age bounds or complex shared decision-making requirements on the final label. A weaker label would limit the commercial upside and slow broad adoption.
Securities litigation risk
High impact · Medium oddsFollowing the NHS-Galleri trial results, new securities class actions were filed against the company in June 2026. These lawsuits allege false and misleading statements. They could lead to substantial legal costs and divert management attention from commercial execution.
MCED competition pressures share
Medium impact · High oddsExact Sciences and Guardant Health launched competing early detection products in 2025. Management noted that new tests with aggressive marketing have caused customer confusion. This requires additional sales force education and could pressure Galleri market share.
Clinical utility doubt after NHS result
High impact · Medium oddsThe NHS-Galleri trial showed a reduction in stage 4 cancer diagnoses, but it did not meet the primary endpoint for a statistically significant combined reduction in stage 3 and 4 cancers. That gives payors and regulators a reason to question whether Galleri improves outcomes enough to justify broad use.
In one breath
What does GRAIL do?
GRAIL sells Galleri, a blood test that screens for a cancer signal across more than 50 cancer types. The company is focused on proving Galleri should be widely used and reimbursed.
Is Galleri FDA approved?
Galleri is currently sold in the United States as a Laboratory Developed Test. Following a favorable FDA advisory committee vote, the company expects a final premarket approval decision in early 2027.
Why does average selling price matter so much?
Average selling price shows how much GRAIL earns per Galleri test before costs. Volume grew 24% in Q3 2026, but ASP dropped to $660, raising concerns about unit economics as legacy royalties return.
What is the Medicare MCED law?
The law created a Medicare coverage benefit category for multi-cancer early detection tests. For GRAIL, the key point is that coverage starts in 2029 and depends on FDA approval and CMS review.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near GRAIL Inc. in Finn's Diagnostics & Research industry ranking.

